Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- May 10, 2012New Territories Include Canada, Mexico and Brazil
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, May 10, 2012 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the lorcaserin marketing and supply agreement...
- May 10, 2012
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, May 10, 2012 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and...
- Apr 30, 2012
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Allen Waxman to the position of Senior Vice...
- Apr 30, 2012H3 Biomedicine to employ Horizon's unique gene editing technology and isogenic cell lines to validate genetically defined drug targets for development of cancer therapeutics
Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines, and
- Apr 19, 2012
Eisai announced today that the company has amended the licensing agreement with Teikoku Pharma USA, Inc. (TPU), a subsidiary of Teikoku Seiyaku...
- Apr 18, 2012
Eisai Inc. announced today that the results of the study, "Randomized Phase III Study 306: Adjunctive Perampanel for Refractory Partial-Onset...
- Apr 16, 2012Clinical Study Seeks to Evaluate MORAb-004 plus best supportive care for Extending Progression-Free Survival of Patients with Chemorefractory Metastatic Colorectal Cancer
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of...
- Mar 27, 2012Morphotek®, Inc. Announces Completion of Enrollment in the FAR-131 Trial for Relapsed Ovarian CancerClinical Study Seeks to Evaluate Farletuzumab in Combination with Standard of Care in First-Relapse Patients with Platinum-Sensitive Ovarian Cancer
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today it has completed enrollment of the FAR-131 clinical trial. The study is a pivotal Phase 3...
- Mar 7, 2012
Woodcliff Lake, NJ, March 6, 2012 - Eisai Inc. today announced that the company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New...
- Mar 5, 2012
Woodcliff Lake, NJ, March 5, 2012 - Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's resubmission of the New Drug Application (NDA)...
- Feb 10, 2012
On February 9, 2012, the U.S. Food and Drug Administration's (FDA's) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 3 with one abstention that the data in the company's...
- Feb 1, 2012
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, February 1, 2012 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified...
- Jan 30, 2012Two Innovative Programs Will Help Eliminate Lymphatic Filariasis By 2020
Tokyo, Japan, January 30, 2012 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai"), as one of the thirteen major research and development-based pharmaceutical...
- Jan 10, 2012
SAN DIEGO and WOODCLIFF LAKE, N.J., Jan. 10, 2012 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has accepted for...
- Jan 9, 2012
Exton, PA, January 9, 2012 -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into two agreements with Fox Chase Cancer Center ("Fox Chase") in Philadelphia, PA...
- Jan 3, 2012
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, January 3, 2012 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that Arena has submitted its response to the Complete Response...
- Jan 3, 2012
Woodcliff Lake, NJ, January 3, 2012 — Eisai Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding...